8.76
4.53%
0.38
전일 마감가:
$8.38
열려 있는:
$8.42
하루 거래량:
484.29K
Relative Volume:
0.74
시가총액:
$1.03B
수익:
-
순이익/손실:
$-174.61M
주가수익비율:
-4.1517
EPS:
-2.11
순현금흐름:
$-165.54M
1주 성능:
+10.47%
1개월 성능:
+7.88%
6개월 성능:
-1.90%
1년 성능:
+15.26%
89 Bio Inc Stock (ETNB) Company Profile
명칭
89 Bio Inc
전화
(415) 432-9270
주소
142 SANSOME STREET, SAN FRANCISCO, CA
ETNB을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
ETNB | 8.76 | 1.03B | 0 | -174.61M | -165.54M | -2.11 |
VRTX | 450.97 | 116.14B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 738.00 | 81.10B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 605.92 | 36.23B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 244.89 | 31.59B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 113.13 | 27.12B | 3.30B | -501.07M | 1.03B | 11.54 |
89 Bio Inc Stock (ETNB) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2022-05-12 | 업그레이드 | Raymond James | Outperform → Strong Buy |
2021-12-20 | 개시 | H.C. Wainwright | Buy |
2021-10-26 | 재개 | Cantor Fitzgerald | Overweight |
2021-07-29 | 재개 | BTIG Research | Buy |
2021-05-25 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
2021-04-21 | 개시 | Cantor Fitzgerald | Overweight |
2020-10-19 | 개시 | Raymond James | Strong Buy |
2020-09-25 | 업그레이드 | BofA Securities | Neutral → Buy |
2020-07-31 | 개시 | Piper Sandler | Overweight |
2020-07-23 | 개시 | BTIG Research | Buy |
2020-07-07 | 개시 | Chardan Capital Markets | Buy |
2019-12-09 | 개시 | BofA/Merrill | Neutral |
2019-12-09 | 개시 | Oppenheimer | Outperform |
2019-12-09 | 개시 | RBC Capital Mkts | Outperform |
2019-12-09 | 개시 | SVB Leerink | Outperform |
모두보기
89 Bio Inc 주식(ETNB)의 최신 뉴스
Non-alcoholic Steatohepatitis (NASH) Treatment Market 2032: Clinical Trials, Medication, EMA, PDMA, FDA Approvals, Epidemiology, Therapies, Companies by DelveInsight - The Globe and Mail
Silvercorp Metals Inc (SVM-T) QuotePress Release - The Globe and Mail
89Bio Inc. Reports Q3 2024 Financial Results - TipRanks
RA CAPITAL MANAGEMENT, L.P. Increases Stake in 89bio Inc - GuruFocus.com
89bio Inc.’s $125 Million Common Stock Offering - Global Legal Chronicle
Finance Watch: Biopharma Stocks Sink On RFK Jr. Nomination To Head HHS - News & Insights
Syncona building Slingshot incubator; Trace launches with $101M - BioCentury
89bio reports potential MASH treatment progress By Investing.com - Investing.com Canada
89bio reports potential MASH treatment progress - Investing.com
89bio's Pegozafermin Shows Promising Results in Advanced MASH Treatment Trial | ETNB Stock News - StockTitan
Viant Technology Inc. Just Recorded A 89% EPS Beat: Here's What Analysts Are Forecasting Next - Yahoo Finance
89bio, Inc. announces public offering and warrant issuance - Investing.com
Janus Henderson Group PLC's Strategic Acquisition in 89bio Inc - GuruFocus.com
FY2024 EPS Estimates for 89bio Lowered by Cantor Fitzgerald - MarketBeat
HC Wainwright Issues Pessimistic Estimate for 89bio Earnings - MarketBeat
BioXcel Q3 Revenue Drops 37%, but Net Loss Narrows Significantly to $13.7M | BTAI Stock News - StockTitan
89bio announces $100 million public stock offering - Investing.com India
SEC Form 424B5 filed by 89bio Inc. - Quantisnow
89bio drops 2%, prices $125M stock offering - MSN
89bio announces $100 million public stock offering By Investing.com - Investing.com Australia
89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants - The Manila Times
Let Poetry Illuminate China's Green City -- The 2nd Nanning International Poetry Week Opens - The Manila Times
89bio Raises $125M in Upsized Public Offering at $8.50 Per Share | ETNB Stock News - StockTitan
89bio, Inc. Announces Upsized Pricing of $125.0 Million Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewswire Inc.
ETNB89bio, Inc. Latest Stock News & Market Updates - StockTitan
89bio announces proposed underwritten public offering of common stock and pre-funded warrants - MSN
BioLife Solutions Surges 30% in Q3 Revenue, Slashes Net Loss by 89% | Earnings Report | BLFS Stock News - StockTitan
89bio Launches $100M Public Offering to Advance Pegozafermin Development | ETNB | ETNB Stock News - StockTitan
GLP-1s push into MASH as semaglutide 2.4 mg hits endpoints - BioWorld Online
89bio Inc (ETNB) Quarterly 10-Q Report - Quartzy
89bio, Inc. (NASDAQ:ETNB) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
HC Wainwright Reaffirms Buy Rating for 89bio (NASDAQ:ETNB) - MarketBeat
FY2028 Earnings Estimate for 89bio Issued By Leerink Partnrs - MarketBeat
TSX Venture Composite Index (JX) QuotePress Release - The Globe and Mail
Raymond James Issues Pessimistic Forecast for 89bio (NASDAQ:ETNB) Stock Price - MarketBeat
Block Inc (SQ-N) QuotePress Release - The Globe and Mail
89bio Reports Third Quarter 2024 Financial Results and Corporate UpdatesSAN FRANCISCO, November 7, 2024 (GLOBE NEWSWIRE) – On November 7, 2024, 89bio, Inc. (NASDAQ: ETNB), a clinical-stage biopharmaceutical company focusing on innovativ - Defense World
89bio Reports Third Quarter 2024 Financial Results and Corporate Updates - The Manila Times
89bio Inc (ETNB) Has A Gold Mine On Its Hands - Stocks Register
Nuvation Bio Reports Third Quarter 2024 Financial Results and Provides Business Update - BioSpace
Harbor Capital Advisors Inc. Purchases 142,032 Shares of 89bio, Inc. (NASDAQ:ETNB) - MarketBeat
89bio to Participate in the UBS Global Healthcare Conference - The Manila Times
89bio to Present at UBS Global Healthcare Conference: Key Investor Updates Coming | ETNB Stock News - StockTitan
Lyft Inc Cl A (LYFT-Q) QuotePress Release - The Globe and Mail
UBS Group Ag ADR (UBS-N) QuotePress Release - The Globe and Mail
89bio (NASDAQ:ETNB) Shares Gap DownHere's What Happened - MarketBeat
Madrigal, 89Bio jump after Novo’s semaglutide shows promise in MASH - Yahoo Finance
89bio's chief technical operations officer sells $226,994 in stock - Investing.com India
89bio's chief technical operations officer sells $226,994 in stock By Investing.com - Investing.com Australia
89bio (NASDAQ:ETNB) Trading 7.3% HigherStill a Buy? - MarketBeat
Coinbase Global Inc Cl A (COIN-Q) QuotePress Release - The Globe and Mail
89 Bio Inc (ETNB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):